首页 | 本学科首页   官方微博 | 高级检索  
检索        

拔毒生肌散治疗非哺乳期乳腺炎脓肿窦道脓腐临床观察
引用本文:曹思涵,唐甜,邵心怡,王聪,冯泽宇,朱智媛,陈绪,姚昶.拔毒生肌散治疗非哺乳期乳腺炎脓肿窦道脓腐临床观察[J].世界中医药,2018(6).
作者姓名:曹思涵  唐甜  邵心怡  王聪  冯泽宇  朱智媛  陈绪  姚昶
作者单位:南京中医药大学附属医院乳腺病科
基金项目:江苏省高校优势学科建设项目II期(012062003010);江苏省中医院高峰学术人才培养(y2014cr06)
摘    要:目的:初步观察拔毒生肌散治疗非哺乳期乳腺炎脓腐,促进创面愈合的临床功效与可能机制。方法:选取非哺乳期乳腺炎脓肿期、窦道期患者20例,分为观察组与对照组,每组10例,观察组将拔毒生肌散均匀洒向并覆盖创面脓腐,以黄芩油纱条覆盖,对照组仅以黄芩油纱条覆盖创面;创面敷药隔日1次,敷药7次为1个疗程。治疗前后进行肿块大小、创面脓腐积分与创周皮肤状况评估,测定创面肉芽IL-6,并进行肝肾功能及尿汞临床安全性测定。结果:观察组的肿块范围评分、创面脓腐评分、创周皮肤状况评分,从治疗第6次起,显著低于对照组(P0.05),其中创周温度从治疗第2次起即显著低于对照组。治疗后观察组脓腐周围肉芽组织中IL-6含量及病理免疫组化表达显著低于对照组(P0.05)。且观察组患者血常规、肝肾功能及尿汞测定均在正常值范围,与对照组比较,差异无统计学意义。结论:拔毒生肌散对非哺乳期乳腺炎患者创面具有良好的提脓去腐功效,显著改善炎性反应而促进愈合,临床使用2周安全,未见不良反应,有一定推广运用价值。

关 键 词:拔毒生肌散  非哺乳期乳腺炎  脓腐  白细胞介素-6  临床安全性
收稿时间:2017/12/1 0:00:00

Clinical Observation on Badu Shengji Powder in the Treatment of Abscess and Sinus of Non-lactating Mastitis
Cao Sihan,Tang Tian,Shao Xinyi,Wang Cong,Feng Zeyu,Zhu Zhiyuan,Chen Xu,Yao Chang.Clinical Observation on Badu Shengji Powder in the Treatment of Abscess and Sinus of Non-lactating Mastitis[J].World Chinese Medicine,2018(6).
Authors:Cao Sihan  Tang Tian  Shao Xinyi  Wang Cong  Feng Zeyu  Zhu Zhiyuan  Chen Xu  Yao Chang
Institution:Department of Breast Disease,Affiliated Hospital of Nanjing University of Chinese Medicine,Nanjing 210029,China
Abstract:To preliminarily observe the clinical efficacy and possible mechanism of the therapeutic effect of Badu Shengji Powder in the treatment of non-lactating mastitis through eliminating pus and necrotic tissues.Methods:A total of 20 patients with non-lactation mastitis were selected in stage of abscess,sinus and divided into the treatment and the control group with 10 cases in each group.In the treatment group,Badu Shengji Powder was evenly spread and covered the pus area of the wound,along with radix scutellariae oil gauze to cover the surface,whereas,in the control group,the wound areas were only covered with radix scutellariae oil gauze.The wounds were treated every other day 7 times for 1 treatment.The size of the tumor mass,the score of the in the wound and the skin condition around the wound were assessed before and after treatment.IL-6 contents in the wound granulation were measured as well as the clinical safety indices of the hepatorenal functions and the level of urine mercury.Results:The scores of breast mass range,the pus and necrotic tissues and the skin conditions beyond wound in the treatment group were significantly lower than those in the control group since the sixth evaluation (P<0.05),among which,the skin temperatures of the wound area were lower than those of control group since the second evaluation.The contents of IL-6 as well as their expressions by histopathologic immunohistochemistry in the peripheral granulation tissue of the treatment group were significantly lower than those in the control group after treatment (P<0.05).The blood routine,hepatoral function and urine mercury of the patients after 14 days of clinical use in the treatment group were all normal and without significant differences as compared with the results of control group.Conclusion:Badu Shengji Powder significantly ameliorated inflammation and promoted wound healing on the patients with non-lactation mastitis through its good efficacies of eliminating pus and narcotic tissues.No clinical adverse events happened within 2 weeks of clinical application.There should be certain values for popularization and application.
Keywords:Badu Shengji Powder  Non-lactating mastitis  Pus and slough  IL-6  Clinical safety
本文献已被 CNKI 等数据库收录!
点击此处可从《世界中医药》浏览原始摘要信息
点击此处可从《世界中医药》下载免费的PDF全文
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号